Micromet Inc. : Buyout Offer for Micromet Triggers Shareholder-Claim Investigation by Goldfarb LLP Securities Attorneys

DALLAS, Feb. 3, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb LLP are investigating whether certain officers and directors of Micromet, Inc. (NASDAQ: MITI) violated shareholder protection laws by agreeing to a tender offer for $11.00 per share to Amgen. Concerned Micromet investors are encouraged to contact securities class action attorney Hamilton Lindley at 877-583-2855 or [e-mail] about their rights and remedies for this potentially low buyout.

"The Wall Street Journal reported that Micromet and Amgen had a collaboration agreement to develop oncology drugs months ago," said Hamilton Lindley. "This buyout appears to be designed for Amgen to take advantage of a pipeline for a leukemia drug so that it can obtain the benefit, to the detriment of the Micromet stockholders. Our proposed shareholder lawsuit seeks to obtain a higher value for shareholders than the current buyout offer."

Goldfarb LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. Micromet stockholders - or anyone with knowledge about this acquisition - should contact lawyer Hamilton Lindley at [e-mail] or 877-583-2855 with questions or concerns.

Hamilton Lindley
Goldfarb LLP
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
[phone] Toll Free Telephone
[phone] Local Phone Number
[phone] Fax Number
www.goldfarbllp.com

SOURCE Goldfarb LLP